Media
Press releases and topics in the spotlight
Welcome to our media section. Check out the latest interviews, news, and press releases from Cinclus Pharma and don’t hesitate to contact us if you need more information.
Latest pressreleases
In the spotlight
A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma. Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Nina Rawal, Trill Impact Ventures, on the investment in Cinclus Pharma
Highlights from the 2024 Annual Report: Interview with Nina Rawal. Trill Impact Ventures views Cinclus Pharma as a strong Life Science candidate with the potential to address unmet medical needs in GERD and H. pylori. Nina Rawal, Co-Head of Ventures…
Kajsa Larsson, CMO, on the upcoming Phase III studies of linaprazan glurate
Highlights from the 2024 Annual Report: Interview with Kajsa Larsson. The study will involve around 500 patients from eight countries in Europe and North America, with up to 100 hospitals and clinics.
Watch the presentation from BioStock Global Forum
Now you can watch the presentation from BioStock Global Forum on May 21st, held by Christer Ahlberg, CEO of Cinclus Pharma.
Cinclus Pharma in media
Kjell Andersson in the Lonza Podcast: A View On: Developing Acid Reflux Therapy
2025-03-06Kjell Anderson, Chief Scientific Officer and Founder of Cinclus Pharma, discusses a novel treatment for acid reflux in this episode ‘A View On: Developing Acid Reflux Therapy’ of the Lonza podcast.
Placera.se lists Swedish stocks offering the biggest upside
2025-01-02Cinclus Pharma is on the list of analysts' favorite stocks when Placera.se lists Swedish stocks offering the biggest upside.
Bengt Julander on Cinclus Pharma in DITV
2024-12-11Bengt Julander, Chairman of one of Cinclus Pharma's largest shareholders, Linc, participated in DITV, saying Cinclus Pharma has the world's best stomach ulcer treatment.
Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
2024-11-28Nyhetsbyrån Direkt about Cinclus Pharma: ABOUT 80-90% OF THE POTENTIAL FOR LINAPRAZAN GLURATE IN THE US
Cinclus Pharma's CEO Christer Ahlberg interviewed by Redeye
2024-09-23Cinclus Pharma's CEO Christer Ahlberg was interviewed by Okee Williams at Redeye AB on September 23, about the company and the development of the drug candidate linaprazan glurate.
